Is InMed (CSE: IN; OTCQB: IMLFF) Building a Billion Dollar Cannabis Business Without Touching The Plant?

Is InMed (CSE: IN; OTCQB: IMLFF) Building a Billion Dollar Cannabis Business Without Touching The Plant?
Is InMed (CSE: IN; OTCQB: IMLFF) Building a Billion Dollar Cannabis Business Without Touching The Plant?

InMed Pharmaceuticals just released a major patent announcement today that could change the face of the medical marijuana industry. Here's why it is important: 

Medical Marijuana has a problem with waste and inefficency when it comes to extracting from a marijuana plant. 

Currently only about 2% of the cannabis plant can be exploited using extraction techniques. Factor in the cost to grow and problems with consistency in the growing process and you can see why we say there is a problem with inefficiency. 

Most of the time is spent extracting THC and CBD, just two of the over 90+ suspected and known cannabinoids in the plant. Imagine if there was an easier way to utilize the other cannabinoids. Think of what that could do to the medical market. 

Today we saw a company take a major step towards solving the inefficiency problem, which could also put billions of dollars into play. 

InMed Pharmaceuticals, Inc. (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the
research and development of novel, cannabinoid-based drug therapies, today announces the filing of a provisional patent application pertaining to the Company’s proprietary biosynthesis program for the manufacture of cannabinoids that are identical to those found in nature.

The patent application, once converted into an international Patent Cooperation Treaty (PCT) application and pursued in key jurisdictions throughout the world, will provide significant commercial protection for InMed’s E. coli-based expression system to manufacture any of the 90+ cannabinoid compounds that may have a medical impact on important human diseases. 

THIS IS HUGE! InMed just filed a patent on their proprietary biosynthesis process that can manufacture any of the medical cannabinoid compounds... without ever touching the plant!!

InMed provisional-patent filing demonstrates their confidence that their biosynthetic capability not only captures the superior economics of bypassing the grow-harvest-extract-purify cycle, but is also vastly more scalable and amenable to long-term systems optimization.

InMed is now poised to do to cannabis medicine what Ely Lilly did back in the early 1980s to the then insulin manufacturing industry.

Namely, transforming an entire industry through biosynthetics and creating a billion dollar plus business.

InMed’s approach here is the best of both worlds really, combining the safety and efficacy of naturally occurring phytocannabinoid molecular structures, with a truly 21st Century production process that also opens the door to a host of promising minor cannabinoids which are not commercially viable to extract from plant sources.

This will be the first in a series of patent applications directed to various aspects of the Company’s biosynthesis program. In particular, these applications focus on the superior nature of E. coli-based expression systems over other approaches; gene optimization for maximizing the production of cannabinoids and related compounds; and other proprietary developments and data.  The company will actively convert this and subsequent provisional patents into national-stage filings in all major commercial jurisdictions, in due course. 

InMed’s cannabinoid biosynthesis program is one of three core assets, which also include the bioinformatics assessment tool to target specific cannabinoids against important diseases, as well as the drug development program, which includes INM-750 for Epidermolysis bullosa and INM-085 for glaucoma.

“This novel approach to the biosynthesis of cannabinoids is a game-changer for drug
development. The importance of producing cannabinoids that are identical to the naturally
occurring compounds cannot be overstated. Many drug development efforts with synthetic
derivatives have failed,”

Dr. Vikramaditya Yadav, Assistant Professor of Chemical and Biological Engineering at University of British Columbia, a co-inventor of the biosynthesis

“In our extensive experimentation, the E. coli system is more robust and more
efficient for the manufacturing of cannabinoids as compared to other microbial platforms.”

The PCT is an international patent law treaty, which provides a unified procedure for filing patent applications to protect inventions in each of its member states. There are 151- member countries within the PCT, enabling near global patent coverage through successful patent prosecution in the U.S., Japan, Europe, Canada, Australia, New Zealand, China, Brazil, Russia, India and many other countries.

This is massive news for investors who want to get in early on a company poised for stratospheric growth. Right now InMed is under valued and under the radar, but with this announcement it might not stay that way for long. 

About InMed 
InMed is a preclinical stage biopharmaceutical company specializing in the research and
development of novel, cannabinoid-based prescription drug therapies utilizing novel drug
delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory,
manufacturing and commercial development activities for its product candidates. InMed’s
proprietary bioinformatics database assessment tool, the biosynthesis manufacturing
process and its drug development programs are the fundamental value drivers of the

For more information, visit

For the Full Release please click here. 
Read More
Thumbnail Photo Credit: N/A by N/A is licensed under N/A N/A
Please see full disclaimers on the website applicable to all content provided by TSI, wherever published or re-published: Disclaimer.

This news release/advertorial is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in small-cap and micro-cap securities is highly speculative and carries an extremely high degree of risk. This website makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Compensation: A thirty-six-thousand-dollar investor relations budget is being managed by The Seed Investor. Any funds leftover after expenses for research, overhead, advertising and public relations related to InMed Pharmaceuticals Inc (ticker symbol (CSE: IN; OTCQB: IMLFF) will be considered profit. The Seed Investor and/or entities related to The Seed Investor hold shares in (CSE: IN; OTCQB: IMLFF) and intend to sell those shares. Please review all investment decisions with a licensed inv­estment advisor.